TP53 and acute myeloid leukemia: TP53 inhibitor eprenetapopt combined with azacytidine for TP53‐mutated MDS and AML was reported to be safe and superior to azacytidine alone in the form of ORR, CR rate, and OS in a phase II trial (NCT03588078).